Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between March 13 and March 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, sold shares of common stock between March 13 and March 15, 2024.
- The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
- On March 13, 2024, Lowenthal sold 1,500 shares at $9 per share and 1,300 shares at $9 per share.
- On March 14, 2024, he sold 205 shares at $9 per share and 239 shares at $9 per share.
- On March 15, 2024, Lowenthal sold 48,295 shares at a weighted average price of $9.1415 (ranging from $9.01 to $9.22) and 48,461 shares at a weighted average price of $9.1413 (ranging from $9.02 to $9.22).
- Following these transactions, Lowenthal directly owns 4,126,822 shares of common stock.
- He also indirectly owns shares through the Richard E. Lowenthal Charitable Remainder UniTrust (1,696,494 1,744,994 shares), the Lowenthal-Tanimoto Family Trust (1,998,499 2,047,199 shares), his spouse (3,276,854 shares), and the Sarina Tanimoto Charitable Remainder UniTrust (1,747,447 shares).
Sentiment
Score: 5
Explanation: The sentiment is neutral. The CEO selling shares is a common occurrence, especially under a pre-arranged plan. The market reaction will depend on the context and the company's performance.
Positives
- The sales were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The CEO selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors.
Risks
- Continued sales by the CEO could put downward pressure on the stock price.
- Investor sentiment could be negatively impacted by the perception of insider selling.
Industry Context
Sales by insiders are common, and the use of 10b5-1 plans is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information. The market will likely assess the size and frequency of these sales in relation to the overall trading volume and the company's performance.
Comparison to Industry Standards
- It is common for executives to utilize 10b5-1 trading plans to diversify their assets.
- The volume of shares sold is relatively small compared to the total outstanding shares, which is a common practice to avoid significant market disruption.
- Comparable companies such as Adamis Pharmaceuticals and Kaleo also have executives who utilize 10b5-1 trading plans.
Stakeholder Impact
- Shareholders may react to the news of the CEO selling shares, potentially impacting the stock price.
- Employees may be concerned about the implications of insider selling, although the 10b5-1 plan mitigates some of these concerns.
Key Dates
| Date | Description |
|---|---|
| January 7, 2020 | Date of Richard E. Lowenthal Charitable Remainder UniTrust and Sarina Tanimoto Charitable Remainder UniTrust |
| April 3, 2006 | Date of Lowenthal-Tanimoto Family Trust U/A DTD |
| March 31, 2023 | Date the Rule 10b5-1 trading plan was entered into |
| March 13, 2024 | Date of first reported transaction |
| March 14, 2024 | Date of second reported transaction |
| March 15, 2024 | Date of third reported transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.